Anika Therapeutics, Inc.
ANIK
$21.38
$0.703.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.12% | -3.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.12% | -3.28% | |||
| Cost of Revenue | 7.07% | -7.18% | |||
| Gross Profit | 11.83% | -0.95% | |||
| SG&A Expenses | -37.12% | 33.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.81% | 11.83% | |||
| Operating Income | 195.51% | -703.87% | |||
| Income Before Tax | 170.11% | -731.02% | |||
| Income Tax Expenses | -69.79% | 122.66% | |||
| Earnings from Continuing Operations | 165.45% | -380.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 165.45% | -1,831.51% | |||
| EBIT | 195.51% | -703.87% | |||
| EBITDA | 309.74% | -226.99% | |||
| EPS Basic | 166.42% | -1,922.93% | |||
| Normalized Basic EPS | 230.32% | -545.97% | |||
| EPS Diluted | 164.22% | -2,480.25% | |||
| Normalized Diluted EPS | 226.64% | -558.28% | |||
| Average Basic Shares Outstanding | -1.49% | -5.20% | |||
| Average Diluted Shares Outstanding | 1.37% | -7.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||